This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
It is currently Thu Jun 20, 2013 12:54 am

View unanswered posts | View active topics


Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]



Post new topic Reply to topic  Page 1 of 1
  [ 4 posts ] 
  Print view Previous topic | Next topic 
Author Message
bromley
 Post subject: Laquinimod trial results
PostPosted: Tue May 01, 2007 2:32 pm 
Offline
Family Elder
User avatar

Joined: Fri Sep 10, 2004 3:00 pm
Posts: 1889
Don't appear that impressive - but it's oral.

http://c.moreover.com/click/here.pl?j913561424&w=464753
Top
 Profile  
 
dignan
 Post subject:
PostPosted: Tue May 01, 2007 3:57 pm 
Offline
Family Elder
User avatar

Joined: Wed Aug 11, 2004 3:00 pm
Posts: 1610
I think what Teva is most interested in is finding out in a phase 3 trial how well laquinimod plays with copaxone.
Top
 Profile  
 
mjs
PostPosted: Tue May 01, 2007 9:51 pm 
Offline
Family Member
User avatar

Joined: Wed Jan 17, 2007 4:00 pm
Posts: 42
bromley wrote:
Don't appear that impressive - but it's oral.


Unimpressive is definitely the right description. Even drugs that reduce lesions *and* relapses are unimpressive - all this drug does is reduce lesions by a mere 38%.

They also say:
Quote:
Significant differences in favor of the 0.6 mg dose were found for most examined secondary and exploratory MRI-based outcome measures. Trends favored the group receiving the 0.6 mg dose on measures of annual relapse rate (0.52 +/- 0.92 vs. placebo 0.77 +/- 1.25; p = 0.21), relapse-free subjects (70.8 percent vs. 62.7 percent; p = 0.33) and time to first relapse (p = 0.14).


...which is quite offensive really. What it should say is:
Quote:
STATISTICALLY INSIGNIFICANT differences in favor of the 0.6 mg dose were found for most examined secondary and exploratory MRI-based outcome measures. Trends favored the group receiving the 0.6 mg dose on measures of annual relapse rate (0.52 +/- 0.92 vs. placebo 0.77 +/- 1.25; p = 0.21), relapse-free subjects (70.8 percent vs. 62.7 percent; p = 0.33) and time to first relapse (p = 0.14).


The "p=" part must always be <0.05. P values of 0.21, 0.33 and 0.14 mean the data is completely and utterly meaningless.

It's like saying that a glass of water a day has a significant impact on MS, however, there is a high probability this may be false.
Top
 Profile  
 
TonyJegs
PostPosted: Wed May 02, 2007 4:18 pm 
Offline
Family Member
User avatar

Joined: Sat Mar 17, 2007 4:00 pm
Posts: 90
Location: Illinios (+ Europe)
mjs wrote:
...which is quite offensive really. What it should say is:
Quote:
STATISTICALLY INSIGNIFICANT differences in favor of the 0.6 mg dose were found for most examined secondary and exploratory MRI-based outcome measures. Trends favored the group receiving the 0.6 mg dose on measures of annual relapse rate (0.52 +/- 0.92 vs. placebo 0.77 +/- 1.25; p = 0.21), relapse-free subjects (70.8 percent vs. 62.7 percent; p = 0.33) and time to first relapse (p = 0.14).


The "p=" part must always be <0.05. P values of 0.21, 0.33 and 0.14 mean the data is completely and utterly meaningless.

It's like saying that a glass of water a day has a significant impact on MS, however, there is a high probability this may be false.


Good work, and thank you the post.

Kind regards,
Tony

_________________
"All truth passes through three stages.
First it is ridiculed.
Second it is violently opposed.
Third it is accepted as being self-evident."
Schopenhauer
Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  Page 1 of 1
  [ 4 posts ] 

Board index » Multiple Sclerosis » Drug Pipeline

All times are UTC - 8 hours [ DST ]

Related topics
 Topics   Author   Replies   Views   Last post 
There are no new unread posts for this topic. Laquinimod results

bromley

0

1115

Wed Sep 28, 2005 6:51 am

bromley View the latest post

There are no new unread posts for this topic. Laquinimod phase II results published

dignan

0

1394

Tue Mar 22, 2005 2:28 pm

dignan View the latest post

There are no new unread posts for this topic. Phase-III Laquinimod trial completed patient enrollment

Frank

0

1161

Tue Nov 18, 2008 7:46 am

Frank View the latest post

There are no new unread posts for this topic. MN 166 trial results

bromley

4

1278

Wed Mar 28, 2007 8:13 am

dignan View the latest post

There are no new unread posts for this topic. Daclizumab trial results

dignan

4

1588

Tue Mar 13, 2007 6:42 am

Lyon View the latest post

 


Who is online

Users browsing this forum: No registered users

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to:  


News News Site map Site map SitemapIndex SitemapIndex RSS Feed RSS Feed Channel list Channel list
Read hundreds of personal Multiple Sclerosis stories on Experience Project. Experience Project is an anonymous community where people connect through their life experiences, made by the same people who built This is MS. With over 30 million personal stories about every possible life experience, you can quickly find people like you!


Interesting: Secret Confessions | Dream Meanings | Ask Questions, Get Answers
This site does not offer, or claim to offer, medical, legal, or professional advice. All treatment decisions should always be made with the full knowledge of your physicians.


All logos and trademarks in this site are property of their respective owners. Content is © 2002-2013 by thisisMS.com.

Advertise on the premier multiple sclerosis forum